Concert Pharmaceuticals Inc. (CNCE) Shares Up 5.9%
Concert Pharmaceuticals Inc. (NASDAQ:CNCE)’s share price shot up 5.9% during mid-day trading on Tuesday . The stock traded as high as $10.24 and last traded at $10.23, with a volume of 285,371 shares trading hands. The stock had previously closed at $9.66.
Several research firms recently issued reports on CNCE. Zacks Investment Research cut Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Brean Capital reaffirmed a “buy” rating on shares of Concert Pharmaceuticals in a research report on Monday, July 11th. Finally, Stifel Nicolaus began coverage on Concert Pharmaceuticals in a research report on Friday, July 1st. They issued a “buy” rating and a $23.00 price objective on the stock. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Concert Pharmaceuticals presently has an average rating of “Buy” and an average price target of $26.43.
The company’s market capitalization is $232.72 million. The firm’s 50 day moving average price is $11.38 and its 200 day moving average price is $12.48.
Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.03. Equities research analysts predict that Concert Pharmaceuticals Inc. will post ($2.51) earnings per share for the current year.
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.